A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. - Wikidata - awgldk - TriplyDB

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q44749300

about

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis Herbal medicines for fatty liver diseases Herbal medicines for fatty liver diseases Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis Nonalcoholic fatty liver disease Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management Treatment of non-alcoholic fatty liver disease Insulin resistance in development and progression of nonalcoholic fatty liver disease Endocrine causes of nonalcoholic fatty liver disease Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway Treatment of nonalcoholic steatohepatitis in adults: present and future Review article: the metabolic syndrome and non-alcoholic fatty liver disease A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis The peroxisome: still a mysterious organelle Molecular mediators of hepatic steatosis and liver injury Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point dixon and three-point IDEAL.Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T.Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease.Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas.Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

P2860

Q22242637-3AB74967-3401-48CD-A58B-2A50CD4A5697 Q24197984-8C60F935-43FD-4A3D-873E-7B537AEFEA21 Q24200256-C3894F6E-4770-444C-B71B-7AC686F30231 Q24236298-9E8E3B79-FB6D-4633-87A9-E8ED30102EC9 Q24246447-98C65A5C-5B06-457C-8850-216011E30EBC Q24555779-AF10317D-28FC-4A0E-9FB2-07B3075DEB7C Q24625697-D1A9A1C5-175B-450F-9472-77007AC380C0 Q24629441-3E619832-D37E-4DC9-9ED4-7D72C3C82DB1 Q24649618-7B2A3A8A-5A55-4906-AB36-F0E5AA4D3E21 Q24655572-65EA4948-1A38-4C0C-92BD-A8EB2B4DE4D6 Q26748687-349383B0-1357-4413-B9D0-728BE33B5D28 Q26780254-27D1E18A-896D-4652-A202-B407A56CB744 Q26800894-5DB771BB-0DAF-4AC4-9967-44FE569B5FB1 Q26852403-C040112B-9517-4BDB-B90F-BEBC7D0308FA Q28192695-CF6E5F59-54A9-49F0-AB16-C86C1393822D Q28728672-CEA32543-5294-449E-B9F2-9915168319C5 Q28754736-29DB4E63-1B82-4BC0-98C7-E03192388E90 Q29616709-1AB29554-FD09-4B21-AA1C-58F0EA26F328 Q29616840-0E1D9925-FB80-4016-BEA0-9397DC8DA370 Q29619314-2AED8CFE-191B-4A5C-A45B-10ADE20422CB Q29619334-D87B7655-6BD8-4D42-B0A8-1C8B90F440C3 Q30389752-43E09458-F4D8-4AEA-928E-C5F95D02B0B5 Q30443852-AB755A48-83FE-4261-8BCB-319E18D94275 Q30467234-86DE6032-B99B-4D4B-85D3-141D3944375B Q31147984-5BE9A969-A9BD-458A-B2C1-519ADE568DA9 Q33268183-3F1CD450-427E-49E0-B330-FC3BF6913A9E Q33409801-FD6C6076-3483-4FFC-B452-B7DFAE29DA51 Q33563333-88B494CA-AB46-4D09-A6DE-A11C0464AA24 Q33607697-82345C9A-9118-4807-9980-A6E9A573C7A2 Q33755829-92471001-1A23-4B22-B7C7-71587390E7B6 Q33836877-174D8C2D-1C3A-43DC-B793-CD05EBE23106 Q33840618-2DC2F2CA-D262-42BB-981E-DCB395E5201F Q33855157-C40F9551-E09E-411E-9157-09EB9BCC7047 Q33867088-5D27618C-80A4-4EDD-9C42-B8D753693186 Q33909796-EA7CDFB1-76E6-48F8-87D1-0272A615B76C Q33937311-8F22CB1F-0C87-4062-B988-6FC35D5EA549 Q34003358-F64648B5-BC52-4FEF-8C24-089877557C47 Q34061979-114440B1-3BB6-4DA0-8B90-C934163DDA6A Q34085058-2641C5CE-D7FD-4F6C-A69C-70A3B90500A9 Q34090872-11A95DAA-1E5C-479D-A5B6-1880607D599A

P2860

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q44749300

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

@en

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

@nl

type

label

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

@en

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

@nl

prefLabel

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

@en

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

@nl

P1433

Q44749300-1B0228C8-8DC0-4001-8A46-4E66D605B62F

P1476

Q44749300-CD0DB70B-501C-4E2D-B4C0-F1E0BCEEBCE3

P2093

Q44749300-0DB5BE7F-8964-421C-8D0B-D9381B5EA3BE

Q44749300-1E0D4367-C9A3-4E15-BF2B-D4AFE10B9E13

Q44749300-2D33E19D-63B4-4CF5-AF59-950421CD1788

Q44749300-332869E9-BFC2-47DF-BF14-213DC36AB6BD

Q44749300-5A82EA8B-36C7-4789-BDC4-C09AADF2C7D5

Q44749300-6FA4F5D8-5648-40B0-8C1F-D0D4B9778080

Q44749300-71B266BC-D3DD-4756-ABE0-E817BE3DC7B1

Q44749300-72EC0FD8-6810-4299-9A1B-77FAD11CEAA7

Q44749300-752C8645-F66E-400B-9E45-68D339A686F5

Q44749300-9A518BFB-9F05-4753-8E01-BF2DB45E7615

P2860

Q44749300-49466259-4C8F-415A-964B-6DBBF4143A4E

P304

Q44749300-5AF050BB-C19E-447D-AAD9-596FBE18E1DD

P31

Q44749300-39E6A2F9-DD4C-4330-BF76-7837E11CB6C6

P356

Q44749300-7C8750F3-08AA-48B0-9439-BA5C2369F9C8

P407

Q44749300-DA2321C4-57DA-400D-9BFB-ED79C36EA9D1

P433

Q44749300-F36C09B4-F1A3-4643-9CC1-F59117372B3B

P478

Q44749300-6E246A5B-E6C7-4412-99A5-2948B4980CB6

P50

Q44749300-52C97706-80D7-4443-A1F3-70522AB4A5B7

Q44749300-A5521C63-2DC4-4103-B588-CEA38A0EEB69

P577

Q44749300-A06BAB9E-E735-460E-8642-DDF71F1F2660

P5875

Q44749300-294861D1-08EB-4AAA-885E-12546CDCD0E3

P698

Q44749300-145AE2A0-7F3F-4486-8458-79AAA36E0AFB

P921

Q44749300-45C065A8-F66D-44CC-93DA-A7716D50DE62

P356

P1433

P1476

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

@en

P2093

Ahalya Premkumar

http://www.w3.org/2001/XMLSchema#string

Alejandro Soza

http://www.w3.org/2001/XMLSchema#string

Edward Doo

http://www.w3.org/2001/XMLSchema#string

Gabriel I Uwaifo

http://www.w3.org/2001/XMLSchema#string

Glen Lutchman

http://www.w3.org/2001/XMLSchema#string

Jay H Hoofnagle

http://www.w3.org/2001/XMLSchema#string

Kittichai Promrat

http://www.w3.org/2001/XMLSchema#string

Marc Ghany

http://www.w3.org/2001/XMLSchema#string

Renee J Freedman

http://www.w3.org/2001/XMLSchema#string

T Jake Liang

http://www.w3.org/2001/XMLSchema#string

P2860

Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy.

P304

188-196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.20012

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Jack A Yanovski

David E. Kleiner

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8894600

http://www.w3.org/2001/XMLSchema#string

P698

14752837

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis